Streptokinase: A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction

PharmacoEconomics

Volumn 10, Issue 3, 1996, Pages 281-310

  Gillis, Jane C ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOKINASE;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW;

EID: 0029743321     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610030-00009     Document Type: Review

References (108)

1. Reckless JPD. Cost implications of lipid-lowering treatments. PharmacoEconomics 1994; 6 (4): 310-23
2. Machecourt J, Dumoulin J, Calop J, et al. Cost effectiveness of thrombolylic treatment for myocardial infarction: comparison of anistreplase, alteplase and streptokinase in 270 patients treated within 4 hours. Eur Heart J 1993 Jan; 14: 75-83
3. Pasternak RC, Braunwald E. Acute myocardial infarction. In: Isselbacher KJ, Braunwald E, Wilson JD, et al., editors. Harrison's principles of internal medicine. 13th ed. v. 1. New York: McGraw-Hill, Inc., 1994: 1066-77
4. Gossage JR. Acute myocardial infarction: reperfusion strategies. Chest 1994 Dec; 106: 1851-66
5. Gonzalez ER, Sypniewski Jr. E. Acute myocardial infarction: diagnosis and treatment. In: DiPiro JT, Talbert RL, Haves PE, et al., editors. Pharmacotherapy: a pathophysiologic approach. New York: Elsevier Science Publishing Co., Ltd., 1989: 213-33
6. Cairns J, Armstrong P, Belenkie I, et al. Canadian Consensus Conference on Coronary Thrombolysis - 1994 recommendations. Can J Cardiol 1994 Jun; 10: 522-9
7. McGlynn S. Criteria for drug usage review of thrombolytics in acute myocardial infarction. PharmacoEconomics 1995 Jan; 7: 25-38
8. Ludlam CA, Bennett B, Fox K, et al. Guidelines for the use of thrombolytic therapy. Thromb Res 1995 May 15; 78: 273-85
9. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction: a review. Drugs 1992 Sep; 44: 293-325
10. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985; 6: 556-85
11. Goa KL, Henwood JM, Stolz JF, et al. Intravenous streptokinase: a reappraisal of its therapeutic use in acute myocardial infarction. Drugs 1990 May; 39: 693-719
12. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity from all randomised trials of more than 1000 patients. Lancet 1994 Feb 5; 343: 311-22
13. IS1S-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988 Aug 13: 349-60
14. Figueredo VM, Amidon TM, Wolfe CL. Adjuvants to thrombolysis after acute myocardial infarction: does adding antiplatelet agents, antithrombotics, or angioplasty make a difference? Postgrad Med 1994 Dec; 96: 45-54
15. Keeley EC, Lange RA. Acute myocardial infarction: role of medical therapy versus primary PTCA. Coron Artery Dis 1995; 6: 759-64
16. Gorlin R. Perspectives on invasive cardiology: the 24th Louis F. Bishop lecture. J Am Coll Cardiol 1994 Feb; 23: 525-32
17. Ellis SG, da Silva ER, Heyndrickx G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute myocardial infarction. Circulation 1994 Nov; 90 (5): 2280-4
18. Reeder GS. Angioplasly or thrombolysis for acute infarction? Z Kardiol 1995; 84 Suppl. 2: 1-4
19. CVD economic impact continues to increase: AHA projects costs to reach $151.1 billion in 1996. FDC Reports Blue Sheet - Health Policy - Biomedical Research 1996 Feb 7: 12-3
20. Peters DH, Benfield P. Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy. PharmacoEconomics 1994 Oct; 6: 370-400
21. Kuntz KM, Lee TH. Cost-effectiveness of accepted measures for intervention in coronary heart disease. Coron Artery Dis 1995 Jun; 6: 472-8
22. Hampton P, Harrison L, Gray D. Demand for hospital services following admission with suspected myocardial infarction in 1983 and 1989. Health Trend 1993; 25 (3): 91-4
23. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995 May 25; 332: 1418-24
24. Zijlstra F, de Boer MJ, Beukema WP, et al. Mortality, reinfarction, left ventricular ejection fraction and costs following reperfusion therapies for acute myocardial infarction. Eur Heart J 1996; 17: 382-7
25. de Boer MJ, van Hout BA, Liem AL, et al. A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. Am J Cardiol 1995 Oct 15; 76: 830-3
26. Simoons ML, Vos J, Martens LL. Cost-utility analysis of thrombolytic therapy. Eur Heart J 1991 Jun; 12: 694-9
27. Naylor CD, Bronskill S, Goel V. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction. Can J Cardiol 1993 Jul-Aug; 9: 553-8
28. Van de Wert F, Topol EJ, Lee KL, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. JAMA 1995 May 24/31; 273 (20): 1586-91
29. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992 Jul 2; 327: 7-13
30. Shanfield SB. Return to work after an acute myocardial infarction: a review. Heart Lung 1990; 19 (2): 109-17
31. Petrie KJ, Weinman J, Sharpe N, et al. Role of patients' view of their illness in predicting return to work and functioning after myocardial infarction: longitudinal study. BMJ 1996 May 11; 312: 1191-4
32. Levin L-A, Perk J, Hedbäck B. Cardiac rehabilitation - a cost analysis. J Intern Med 1991 Nov; 230: 427-34
33. Schwartz JS. Necessity of using intermediate outcomes to proxy long term effects: the example of thrombolytics PharmacoEconomics 1995 Jan; 7: 7-13
34. Battershill PE, Benfield P, Goa KL. Streptokinase: a review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients. Drugs Aging 1994 Jan; 4: 63-86
35. The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336 (8707): 71-5
36. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. IS1S-3: a randomised comparison of streptokinase v.v tissue plasminogen activator v.v anistreplase and of aspirin plus heparin is aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992 Mar 28; 339: 753-70
37. Hampton JR, Schröder R, Wilcox RG. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995 Aug 5; 346: 329-36
38. GISSI-2 and International Study Group. Six-month survival in 20 891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Eur Heart J 1992; 13: 1692-7
39. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993 Sep 2; 329: 673-82
40. GUSTO: 1-year results. Lysis Update (Issue 8). Sydney: Adis International, 1994.
41. Tebbe U, Michels R, Adgey J, et al. Thrombolysis with saruplase is at least as effective in AMI as streptokinase: COMPASS double-blind study in 3089 patients [abstract]. J Am Coll Cardiol 1996; 27 (2) Suppl. A: 166A
42. Baigent C, Collins R, Isis CG, et al. ISIS-2: 4-year mortality follow-up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction [abstract]. Circulation 1993 Oct; 88 (Pt2) Suppl.: 1-291
43. Simoons ML, Vos J, Tijssen JGP, et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989 Dec; 14: 1609-15
44. American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic-Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). ACC/AHA guidelines for the early management of patients with acute myocardial infarction. Circulation 1990 Aug; 82 (2): 664-707
45. Kennedy JW. The relative merits of direct angioplasty versus intravenous thrombolytic therapy for the treatment of acute myocardial infarction. Am J Ther 1995; 2: 151-3
46. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993 Nov 25; 329: 1615-22
47. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82 (3): 781-91
48. Naylor CD, Jaglal SB. Impact of intravenous thrombolysis on short-term coronary revascularization rates. A meta-analysis. JAMA 1990 Aug 8; 264: 697-702
49. Woo KS, White HD. Comparative tolerability profiles of thrombolytic agents: a review. Drug Saf 1993; 8 (1): 19-29
50. Elliott JM, Cross DB. Cederholm-Willlams SA, et al. Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy. Am J Cardiol 1993 March 15; 71: 640-5
51. Fears R, Ferres H, Glasgow E, et al. Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. Br Heart J 1992 Aug; 68: 167-70
52. Vermeer F, Simoons ML, de Zwaan C, et al. Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands. Br Heart J 1988 May; 59: 527-34
53. Martens L, van Doorslaer E. Dealing with discounting. An application to the cost-effectiveness of intracoronary thrombolysis with streptokinase. Int J Technol Assess Health Care 1990; 6: 139-45
54. Kalish SC, Gurwitz JH, Krumholz HM, et al. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995 Jun; 10: 321-30
55. Midgette AS, Wong JB, Beshansky JR, et al. Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 1994 Apr-Jun; 14: 108-17
56. Goel V, Naylor CD. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. Can J Cardiol 1992 Jan-Feb; 8: 31-8
57. Elliott JM, Williams BF, White HD. Streptokinase and lifestyle outcome in survivors of myocardial infarction. N Z Med J 1992 May 13; 105: 163-4
58. Leimbach Jr WN, Hagan AD, Vaughan HL, et al. Cost and efficacy of intravenous streptokinase plus PTCA for acute myocardial infarction when therapy is initiated in community hospitals. Clin Cardiol 1988 Nov; 11: 731-8
59. Brophy JM, Joseph L. Placing trials in context using Bayesian analysis: GUSTO revisited by Reverend Bayes. JAMA 1995; 273 (11): 871-5
60. Patrick DL. Health-related quality of life in pharmaceutical evaluation: forging progress and avoiding pitfalls. PharmacoEconomics 1992; 1 (2): 76-8
61. Glasziou PP, Bromwich S, Simes RJ, et al. Quality of life six months after myocardial infarction treated with thrombolytic therapy. Med J Aust 1994 Nov 7; 161: 532-6
62. Mark DB, Naylor CD, Hlatky MA, et al. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med 1994 Oct 27; 331: 1130-5
63. Brophy JM, Joseph L. Quality of life after myocardial infarction: Canada versus the United States [letter]. N Engl J Med 1995 Feb 16; 332: 469-70
64. Greenfield S, Kaplan S. Quality of life after myocardial infarction: Canada versus the United States [letter]. N Engl J Med 1995 Feb 16; 332:471
65. Doherty N. Quality of life after myocardial infarction: Canada versus the United States [letter]. New Engl J Med 1995; 16; 332: 469
66. Farkouh ME, Lang JD. Sackett DL. Thrombolytic agents: the science of the art of choosing the better treatment. Ann Intern Med 1994 May 15; 120: 886-8
67. Neuhaus K-L. More on thrombolysis and hemorrhagic stroke. Circulation 1995 Nov 15; 92: 2794-5
68. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-1 trial. Circulation 1995 Nov 15; 92: 2811-8
69. Ridker PM. From GISSI-2 to ISIS-3 to GUSTO-1: making sense of the large-scale thrombolytic trials. Pharmacol Ther 1995 Nov: 12S-8S
70. Gore JM. Patient selection issues in the use of thrombolytic therapy in patients with acute myocardial infarction. Z Kardiol 1993; 82 Suppl. 2: 143-6
71. Anderson JL. Medical therapy for elderly patients who have had myocardial infarction: too little to the late in life? Ann Intern Med 1996 Feb 1; 124 (3): 335-7
72. European Secondary Prevention Study Group. Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996 May 4; 347: 1203-7
73. Fendrick AM, Ridker PM, Bloom BS. Improved health benefits of increased use of thrombolytic therapy. Arch Intern Med 1994 Jul 25; 154: 1605-9
74. National Heart Attack Alert Program Coordinating Committee 60 M to TWG. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994; 23 (2): 311-29
75. Weaver WD. Time to thrombolytic treatment: factors affecting delay and their influence on outcome. J Am Coll Cardiol 1995 Jun; 25 Suppl.: 3S-9S
76. Brophy JM. Interpreting results from thrombolytic megatrials: distinguishing fact from fiction. Can J Cardiol 1996 January; 12 (1): 89-92
77. Lee KL, Califf RM, Simes J, et al. Holding GUSTO up to the light. Ann Intern Med 1994 May 15; 120: 876-81
78. Stringer KA, Lindenfeld JA. The GUSTO Trial: is the open-artery hypothesis proven? Ann Pharmacother 1994 Jan; 28: 97-8
79. de Leon Jr AC, Farmer CA, King G, et al. Chest pain evaluation unit: a cost-effective approach for ruling out acute myocardial infarction. South Med J 1989; 82 (9): 1083-9
80. Shesser R, Smith M. The chest pain emergency department and the outpatient chest pain evaluation center: revolution or evolution? Ann Emerg Med 1994; 23: 334-41
81. Gibler WB. Evaluating patients with chest pain in the ED: improving speed, efficiency, and cost-effectiveness, or teaching an old dog new tricks. Ann Emerg Med 1994 Feb; 23: 381-2
82. Gaspoz J-M, Lee TH, Weinstein MC, et al. Cost-effectiveness of a new short-stay unit to 'rule out' acute myocardial infarction in low risk patients. J Am Coll Cardiol 1994 Nov 1; 24: 1249-59
83. Newby LK, Califf RM, Guerci A, et al. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) trial. J Am Coll Cardiol 1996 Mar 1; 27 (3): 625-32
84. Wilkinson P, Stevenson R, Ranjadayalan K, et al. Early discharge after acute myocardial infarction: risks and benefits. Br Heart J 1995 Jul; 74: 71-5
85. Gurwitz JH, Gore JM, Goldberg RJ, et al. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med 1996 Feb 1; 124: 283-91
86. Tresch DD, Berkompas D. Management of acute myocardial infarction in the elderly. Cleve Clin J Med 1995 May-Jun; 62: 156-62
87. Verstraete M, Collen D. Optimising thrombolytic therapy in elderly patients with acute myocardial infarction. Drugs Aging 1996 Jan; 8 (1): 17-22
88. Sleight P. Streptokinase is still the agent of choice for most patients with myocardial infarction. Am J Ther 1995 Feb; 2: 128-35
89. Brophy JM. Thrombolysis from P values to public health. Can J Cardiol 1994 Dec; 10: 997-9
90. Eddy DM. Principles for making difficult decisions in difficult times. JAMA 1994; 271 (22): 1792-8
91. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146 (4): 473-81
92. Cairns J, Armstrong P, Belenkie I, et al. Canadian Consensus Conference on Coronary Thrombolysis - 1994 update. Can J Cardiol 1994 Jun; 10: 517-21
93. Naylor CD, Armstrong PW. From thrombolytic megatrials to clinical policy-making: facing the facts. Can J Cardiol 1995 Jun; 11: 472-6
94. Plotnick GD, Ziskind AA, Vogel RA. Survey of practicing cardiologists in Maryland on their choice of thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1992 Feb 1; 69: 327-30
95. Hindle H, Norheim JK, Renger R. Rural Alberta thrombolysis study: survey of practice patterns for managing acute myocardial infarction. Can Fam Phys 1995 Jul; 41: 1180-7
96. Brody B, Wray N, Bame S, et al. The impact of economic considerations on clinical decisionmaking: the case of thrombolytic therapy. Med Care 1991 Sep; 29: 899-910
97. Lessler DS, Avins AL. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy. Arch Intern Med 1992 Aug; 152: 1665-72
98. Stanek EJ, Tucker PP, Cheng JWM. Patient preferences of tPA and Streptokinase [abstract no. 2835]. Circulation 1994 Oct; 90 (4 Pt 2): 527
99. Jaeschke R, Guyatt GH, Cook D. Quality of life instruments in the evaluation of new drugs. PharmacoEconomics 1992; 1 (2): 84-94
100. Using drug utilisation review to assess the appropriateness of thrombolytic therapy. Drug Ther Perspect 1995 May 1; 5: 14-6
101. Kahn KL, Pearson ML, Harrison ER, et al. Health care for black and poor hospitalized Medicare patients. JAMA 1994 Apr 20; 271 (15 1169-1174)
102. Peterson ED, Wright SM, Daley J, et al. Racial variation in cardiac procedure use and survival following acute myocardial infarction in the Department of Veterans Affairs. JAMA 1994 Apr 20; 271: 1175-80
103. Pashos CL, Normand S-LT, Garfinkle JB, et al. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol 1994 Apr; 23: 1023-30
104. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med 1995 Aug 31; 333: 565-72
105. Every NR, Fihn SD, Maynard C, et al. Resource utilization in treatment of acute myocardial infarction: staff-model health maintenance organization versus fee-for-service hospitals. J Am Coll Cardiol 1995 Aug; 26: 401-6
106. Carlisle DM, Siu AL, Keeler EB, et al. HMO vs fee-for-service care of older persons with acute myocardial infarction. Am J Public Health 1992 Dec; 82: 1626-30
107. Krumholz HM. Health maintenance organizations, fee for service and the care of patients with acute myocardial infarction. J Am Coll Cardiol 1995 Aug; 26: 407-8
108. Ayanian JZ. Race, class, and the quality of medical care. JAMA 1994 Apr 20; 271: 1207-8